

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Invesco Ltd.</u>  (Last) (First) (Middle) 1555 PEACHTREE STREET NE SUITE 1800  (Street) ATLANTA GA 30309  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Evofem Biosciences, Inc. [ EVFM ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>04/10/2019</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)				4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price					

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Right to Purchase	\$4.5	04/10/2019		J <sup>(1)</sup>		2,222,222		04/11/2019	06/10/2019	Common Stock	2,222,222	\$0.0001	2,777,778 <sup>(2)</sup>	I	See Footnote <sup>(3)</sup>
Right to Purchase	\$6.38	04/10/2019		J <sup>(1)</sup>		555,556		(4)	(5)	Common Stock	555,556	\$0.0001	2,777,778 <sup>(2)</sup>	I	See Footnote <sup>(3)</sup>

**Explanation of Responses:**

- On April 10, 2019, Invesco Ltd. entered into a Securities Purchase Agreement with the Issuer (the "Securities Purchase Agreement"), pursuant to which Invesco Ltd. has the right, until June 10, 2019, to purchase 2,222,222 shares of common stock at a purchase price of \$4.50 per share and warrants to purchase an additional 555,556 shares of common stock at an exercise price equal to \$6.38 per share.
- This number does not include the 212,765 warrants owned by Invesco Ltd. as of the date of this Form 4. Pursuant to the Securities Purchase Agreement, upon and subject to the second closing contemplated therein, Invesco Ltd. will surrender for cancellation warrants to purchase 212,765 shares of common stock existing and outstanding as of the date of the Securities Purchase Agreement.
- Invesco Ltd. is the beneficial owner of 11,812,910 shares of common stock and warrants to purchase 212,765 common shares acquired by its affiliates, Invesco High Income Fund and Invesco Income Fund.
- The warrants are exercisable six (6) months following the original issue date
- The warrants expire seven (7) years following the original issue date.

**Remarks:**

Nancy Tomassone, Global Assurance Officer 04/15/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.